Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-25-120055
Filing Date
2025-12-10
Accepted
2025-12-10 15:47:06
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7331
  Complete submission text file 0001213900-25-120055.txt   9263
Mailing Address 245 FIRST STREET RIVERVIEW II 18TH FLOOR CAMBRIDGE MA 02142
Business Address 245 FIRST STREET RIVERVIEW II 18TH FLOOR CAMBRIDGE MA 02142 239-302-1707
Enveric Biosciences, Inc. (Subject) CIK: 0000890821 (see all company filings)

EIN.: 954484725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-53543 | Film No.: 251561853
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 120 NEWPORT CENTER DR STE 250 NEWPORT BEACH CA 926660
Business Address 120 NEWPORT CENTER DR STE 250 NEWPORT BEACH CA 926660 9498757003
NORTHSTRIVE FUND II LP (Filed by) CIK: 0002099270 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A